Tivozanib hydrochloride by AVEO Pharmaceuticals for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role …